EMERYVILLE, Calif.--(BUSINESS WIRE)--Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced it will introduce its new preclinical drug candidate, NTX-472, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago from May 31 to June 4.
NTX-472 uses engineered mRNA-encoded proteins to simultaneously engage CD20, CD19, and CD47. Nutcracker Therapeutics is currently developing the candidate for the treatment of B cell lymphoma.
Additionally, Dr. Nicole Fay, director of pharmacology and product lead for NTX-250 (the company’s lead candidate), will be presenting and participating in a panel discussion at the 10th Sachs Oncology Innovation Forum (OIF) on May 31, which runs concurrently with the ASCO annual meeting.
Poster Presentation at ASCO 2024
Title: Development of NTX-472, a formulated mRNA therapy targeting CD20, CD19, and CD47, for treatment of B-cell lymphoma
Abstract Number: 2537
Session Title: Developmental Therapeutics — Immunotherapy
Session Location: Hall A
Session Date and Time: June 1, 9:00 a.m. – 12:00 p.m. CDT
Lead Author: Adrienne Sallets
Abstract titles are available on the ASCO conference website. More information about the conference can be found on ASCO’s website.
Sachs OIF Activities
Location:
Waldorf Astoria Chicago Hotel
11 E Walton St, Chicago, IL 60611
Panel Discussion: New Methods of Therapeutic Delivery for Oncology
Date and Time: May 31, 2:40 p.m. CDT
Speaker: Nicole Fay
Corporate Presentation
Presentation Track: A, Room Faulkner
Date and Time: May 31, 11:50 a.m. CDT
Speaker: Nicole Fay
More details about the event can be found on the OIF website, along with the full agenda.
About Nutcracker Therapeutics, Inc.
Nutcracker Therapeutics, Inc., is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA platform that encompasses the design, delivery, and manufacturing of RNA medicines. Armed with this high-tech advantage, the company has initiated multiple therapeutic programs with the support of clinical investigators at leading institutions. Nutcracker Therapeutics’ technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in speed and capacity scaling over other RNA manufacturing approaches.
For more information, visit www.nutcrackerx.com/.
